Leiden Jeffrey M's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Nov 17, 2025
- Accession no.
- 0000875320-25-000234
- Filed
- Nov 17, 2025
- Trade date
- Nov 13-14, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 8 non-derivative transactions and 3 derivative transactions. Open-market sales total $32.3M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leiden Jeffrey MCIK 0001242825 | Director, Officer (Executive Chairman) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 13, 2025 | Common Stock | MOption exerciseAcquired | +19,688 | $91.05 | +$1,792,592.4 | 43,714 | Direct | |
| Nov 13, 2025 | Common Stock | SSaleDisposed | −18,528 | $440.22F2,F3 | −$8,156,396.16 | 25,186 | Direct | |
| Nov 13, 2025 | Common Stock | SSaleDisposed | −1,160 | $441.05F2,F4 | −$511,618 | 24,026 | Direct | |
| Nov 14, 2025 | Common Stock | MOption exerciseAcquired | +13,835 | $91.05 | +$1,259,676.75 | 37,861 | Direct | |
| Nov 14, 2025 | Common Stock | MOption exerciseAcquired | +39,769 | $86.52 | +$3,440,813.88 | 77,630 | Direct | |
| Nov 14, 2025 | Common Stock | SSaleDisposed | −32,234 | $440.30F2,F5 | −$14,192,630.2 | 45,396 | Direct | |
| Nov 14, 2025 | Common Stock | SSaleDisposed | −21,330 | $441.35F2,F6 | −$9,413,995.5 | 24,066 | Direct | |
| Nov 14, 2025 | Common Stock | SSaleDisposed | −40 | $442.00 | −$17,680 | 24,026 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 13, 2025 | Common Stock | MOption exerciseDisposed | −19,688 | $0.00 | $0 | 13,836 | Direct | |
| Nov 14, 2025 | Common Stock | MOption exerciseDisposed | −13,835 | $0.00 | $0 | 1 | Direct | |
| Nov 14, 2025 | Common Stock | MOption exerciseDisposed | −39,769 | $0.00 | $0 | 63,781 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Referenced by the price of 4 transactions in Table I.
- F3
Open market sales reported on this line occurred at a weighted average price of $440.22 (range $440.00 to $440.99).
Referenced by the price of 1 transaction in Table I.
- F4
Open market sales reported on this line occurred at a weighted average price of $441.05 (range $441.00 to $441.10).
Referenced by the price of 1 transaction in Table I.
- F5
Open market sales reported on this line occurred at a weighted average price of $440.30 (range $440.00 to $440.99).
Referenced by the price of 1 transaction in Table I.
- F6
Open market sales reported on this line occurred at a weighted average price of $441.35 (range $441.00 to $441.99).
Referenced by the price of 1 transaction in Table I.